Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | AHCY | P23526 | 6/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11076308 | 0.80 | AHCY (0.57) | ADORA2AADORA2BADORA1JAK2AHCY | |
| SCHEMBL9108201 | 0.79 | ADORA2A (0.36) | ADORA2AADORA2BADORA1SMN1; SMN2AHCY | |
| 3-Ethyladenine SCHEMBL48200 | 0.77 | ADORA2A (0.50) | ADORA2AADORA2BADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL5513295 | 0.77 | ADORA2A (0.35) | ADORA2AADORA2BADORA1SMN1; SMN2AHCY | |
| 3-Propyladenine SCHEMBL15756434 | 0.75 | ADORA2A (0.53) | ADORA2AADORA2BADORA1ADORA3SMN1; SMN2 | |
| 3-Benzyladenine SCHEMBL5352368 | 0.71 | ADORA2A (0.56) | ADORA2ASMN1; SMN2PI4KAPI4K2BPI4K2A | |
| SCHEMBL1882911 | 0.71 | — | — | |
| SCHEMBL1798270 | 0.70 | ADORA2A (0.72) | ADORA2AADORA2BADORA1AHCYPI4KA | |
| SCHEMBL9778803 | 0.70 | ADORA2A (0.63) | ADORA2AADORA2BADORA1ADORA3AHCY | |
| SCHEMBL21121959 | 0.70 | KCNH2 (0.44) | ADORA2ASMN1; SMN2JAK2PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175010-A1 | Methods of Library Preparation | ILLUMINA, INC. (US) | 2024-05-30 | — | — | US | claimed |
| WO-2024059788-A2 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | Chen cheng yao | 2024-03-21 | — | — | WO | claimed |
| CN-117651767-A | Improved methods for isothermal complementary DNA and library preparation | ILLUMINA公司 | 2024-03-05 | — | — | CN | claimed |
| EP-4314279-A1 | IMPROVED METHODS OF LIBRARY PREPARATION | Illumina, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4314282-A1 | IMPROVED METHODS OF ISOTHERMAL COMPLEMENTARY DNA AND LIBRARY PREPARATION | Illumina, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117062910-A | Improved library preparation method | ILLUMINA公司 | 2023-11-14 | — | — | CN | claimed |
| US-20240209396-A1 | SMALL CAS PROTEINS AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-111278974-B | Hook probe, nucleic acid ligation method, and method for constructing sequencing library | 深圳华大智造科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240175010-A1 | Methods of Library Preparation | ILLUMINA, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240150753-A1 | METHODS OF ISOTHERMAL COMPLEMENTARY DNA AND LIBRARY PREPARATION | ILLUMINA, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024059788-A2 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | Chen cheng yao | 2024-03-21 | — | — | WO | disclosed |
| US-20240076651-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-07 | — | — | US | disclosed |
| CN-117651767-A | Improved methods for isothermal complementary DNA and library preparation | ILLUMINA公司 | 2024-03-05 | — | — | CN | disclosed |
| US-6046036-A | FOR INCREASING SURVIVAL RATE OF NON-TARGET CELLS SUCH AS HEMATOPOIETIC CELLS WHEN CONTACTED WITH ANTICARCINOGENIC/DNA-DAMAGING AGENTS DURING MULTIAGENT CHEMOTHERAPY PROTOCOLS OR IN FANCONI'S ANEMIA | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1998017684-A2 | DNA SEQUENCES ENCODING FUSIONS OF DNA REPAIR PROTEINS AND USES THEREOF | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0651825-B1 | METHODS AND DIAGNOSTIC KITS FOR DETERMINING THE TOXICITY OF A COMPOUND UTILIZING BACTERIAL STRESS PROMOTERS FUSED TO REPORTER GENES | HARVARD COLLEGE (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5589337-A | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1996-12-31 | — | — | US | disclosed |
| US-5585232-A | Methods and diagnostic kits for determining toxicity utilizing E. coli stress promoters fused to reporter genes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0651825-A1 | METHODS AND DIAGNOSTIC KITS FOR DETERMINING THE TOXICITY OF A COMPOUND UTILIZING BACTERIAL STRESS PROMOTERS FUSED TO REPORTER GENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994001584-A1 | METHODS AND DIAGNOSTIC KITS FOR DETERMINING TOXICITY UTILIZING BACTERIAL STRESS PROMOTERS FUSED TO REPORTER GENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076651-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | ADA, APOBEC3A, CDA | ADORA2A 360/4885ADORA2B 933/4885ADORA1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.